Cairo – Mubasher: Glaxo SmithKline turned to losses in the second quarter of 2016, as it logged losses of EGP 38.3 million ($4.3 million).
The drug company posted losses of EGP 26.7 million ($3.01 million) for the same period of the previous year.
As for the first half of 2016, the company narrowed its losses by 66.7% to reach EGP 34.6 million ($3.9 million), against 103.9 million ($11.7 million) a year earlier.
